

BIOTIME INC  
Form 8-K  
September 09, 2010  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **September 3, 2010**

**BioTime, Inc.**  
(Exact name of registrant as specified in its charter)

**California**                      **1-12830**                      **94-3127919**  
(State or other jurisdiction of    (Commission File Number) (IRS Employer Identification  
incorporation)                      No.)

**1301 Harbor Bay Parkway, Suite 100**  
**Alameda, California 94502**  
(Address of principal executive offices)

**(510) 521-3390**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

*Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.*

## **Section 5-Corporate Governance and Management**

### **Item 5.02-Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On September 3, 2010 our Chief Financial Officer, Steven A. Seinberg, resigned his position effective September 17, 2010. Mr. Seinberg, who is an attorney, is returning to the practice of law at a private firm. Mr. Seinberg has agreed to assist us in transition tasks on a consulting basis.

Our Senior Vice President and Chief Operating Officer, Robert W. Peabody, will take on the duties of the chief financial officer on an interim basis. Mr. Peabody is a certified public accountant and has worked in the financial management area for his entire career. His experience includes public accounting with Ernst & Young, as a CFO for a regional transportation company, and as a financial executive for a Fortune 500 specialty chemical manufacturer. Mr. Peabody also has considerable experience in the field of biotechnology including his participation in the founding of Geron Corporation.

## **Section 9-Financial Statements and Exhibits**

### **Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release Dated September 8, 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOTIME, INC.**

Date: September 8, 2010 By: /s/ Steven A. Seinberg  
Chief Financial Officer

3

---

Exhibit Number   Description

99.1            Press Release Dated September 8, 2010